Ebaa F. Al-Obeidi

Ebaa Al-Obeidi practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Ebaa Al-Obeidi's NPI, 1619472693, was assigned on March 29, 2018. Ebaa Al-Obeidi graduated from UC Irvine School of Medicine in 2018. Ebaa Al-Obeidi holds California license A164569.

Ebaa Al-Obeidi's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Ebaa Al-Obeidi's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Ebaa Al-Obeidi to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Ebaa Al-Obeidi practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Ebaa Al-Obeidi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Ebaa Al-Obeidi is board certified in internal medicine by the American Board of Internal Medicine. Ebaa Al-Obeidi is licensed in California.

CMS data shows 100 Medicare services from Ebaa Al-Obeidi across 3 procedure codes in 2024, for 41 Medicare patients. Medicare paid $5,726 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 41 Medicare patients who saw Ebaa Al-Obeidi in 2024. The largest group is 75 to 84, with 19 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Ebaa Al-Obeidi's median patient age at 67, with 50% women.

In 2024, Ebaa Al-Obeidi wrote 299 Medicare Part D claims for 34 patients. 75% of them were for generic drugs. CMS names the drug for 205 of them, across 12 drugs with 11 or more claims each, at $488,951 in total drug cost. In 2023, CMS named 226 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Ebaa Al-Obeidi for performance year 2024, reported as part of a group. Ebaa Al-Obeidi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Ebaa Al-Obeidi as offering telehealth.

Dmand AI links 9 papers to Ebaa Al-Obeidi, published from 2018 to 2024. 2018 was the busiest year, with 2. The most frequent topics are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms and Protein Kinase Inhibitors. Ebaa Al-Obeidi's most frequent co-authors are David Raymond Gandara, MD, Karen L. Kelly, MD and Tianhong Li, MD, PhD.

CMS Open Payments shows 2 general payments to Ebaa Al-Obeidi from 2 drug and device companies in 2024. Food and beverage make up the largest share, 55% of the total. EMD Serono, Inc. paid the most, $22.

Ebaa Al-Obeidi graduated from UC Irvine School of Medicine in 2018.

Ebaa Al-Obeidi is in network with 7 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.